1
|
Tang D, Malchesky P, Omokawa S, Matsushita M, Davies C, Nosé Y. Temperature Effect on Bilirubin Adsorption with the Anion Exchange Resin BR-601. Int J Artif Organs 2018. [DOI: 10.1177/039139888901201011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Plasma perfusion with the anion exchange resin BR-601 is an effective method to treat patients with hepatic failure and hyperbilirubinemia. To assess the temperature dependency of bilirubin sorption in vitro, isotherm studies with human pathologic plasmas and an albumin-bilirubin solution were carried out. Results showed that BR-601 was more effective at 37°C and 42°C than at 4°C and 25°C for sorbing bilirubin. Therefore, plasma sorption at near physiologic temperature would be expected to be more efficient for plasma treatment than sorption at ambient temperature.
Collapse
Affiliation(s)
- D.H. Tang
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio - USA
| | - P.S. Malchesky
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio - USA
| | - S. Omokawa
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio - USA
| | - M. Matsushita
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio - USA
| | - C.R. Davies
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio - USA
| | - Y. Nosé
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio - USA
| |
Collapse
|
2
|
Malchesky P, Takahashi T, Iwasaki K, Harasaki H, Nosé Y. Conjugated Human Hemoglobin as a Physiological Oxygen Carrier - Pyridoxalated Hemoglobin Polyoxyethylene Conjugate (PHP). Int J Artif Organs 2018. [DOI: 10.1177/039139889001300711] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Problems associated with specific physiological properties of Hb-based blood substitutes, such as a low P50, short plasma half-life and nephrotoxicity are still major issues to be addressed. Extensive investigations aimed at overcoming these problems have resulted in the preparation of pyridoxalated-hemoglobin-polyoxyethylene conjugate (PHP). PHP was developed from human hemoglobin by two major chemical modifications; pyridoxylation for the purpose of lowering the oxygen affinity (P50 of 19.5 ± 1.2 mmHg), and coupling with polyoxyethylene (POE) to increase its molecular weight (to approximately 90 kdaltons). The circulating half-life of PHP is about 40 hours in dogs. Toxicologicai and physiological studies including renal function assessments have demonstrated that PHP does not have untoward effects on major organ functions. Its efficacy in transporting oxygen has been shown in ET and intracoronary perfusion, and in in vitro studies with sickle cells. Studies to date suggest that PHP is a promising candidate as a physiological oxygen carrier. In this paper the properties of PHP, its safety and efficacy aspects, and its potential as a clinical oxygen carrier are reviewed based on studies conducted in the Author's laboratory.
Collapse
Affiliation(s)
- P.S. Malchesky
- Department of Artificial Organs, The Cleveland Clinic Foundation, Cleveland, Ohio - U.S.A
| | - T. Takahashi
- Department of Artificial Organs, The Cleveland Clinic Foundation, Cleveland, Ohio - U.S.A
| | - K. Iwasaki
- Department of Artificial Organs, The Cleveland Clinic Foundation, Cleveland, Ohio - U.S.A
| | - H. Harasaki
- Department of Artificial Organs, The Cleveland Clinic Foundation, Cleveland, Ohio - U.S.A
| | - Y. Nosé
- Department of Artificial Organs, The Cleveland Clinic Foundation, Cleveland, Ohio - U.S.A
| |
Collapse
|
3
|
Nakazawa T, Ohara Y, Benkowski R, Makinouchi K, Takami Y, Ohtsubo S, Kawahito K, Tasai K, Glueck J, Noon G, Sueoka A, Schmallegger H, Schima H, Wolner E, Nosé Y. A Pivot Bearing-Supported Centrifugal Pump for a Long-Term Assist Heart. Int J Artif Organs 2018. [DOI: 10.1177/039139889702000407] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
A pivot bearing-supported centrifugal blood pump has been developed. It is a compact, cost effective, and anti-thrombogenic pump with anatomical compatibility. A preliminary evaluation of five paracorporeal left ventricular assist studies were performed on pre-conditioned bovine (70-100 kg), without cardiopulmonary bypass and aortic cross-clamping. The inflow cannula was inserted into the left ventricle (LV) through the apex and the outflow cannula affixed with a Dacron vascular graft was anastomosed to the descending aorta. All pumps demonstrated trouble free performance over a two-week screening period. Among these five studies, three implantations were subjected for one month system validation studies. All the devices were trouble free for longer than 1 month. (35, 34, and 31 days). After achieving one month studies, all experiments were terminated. There was no evidence of device induced thrombus formation inside the pump. The plasma free hemoglobin levels were within normal ranges throughout all experiments. As a consequence of these studies, a mass production model C1E3 of this pump was fabricated as a short-term assist pump. This pump has a Normalized Index of Hemolysis of 0.0007 mg/100L and the estimated wear life of the impeller bearings is longer than 8 years. The C1E3 will meet the clinical requirements as a cardiopulmonary bypass pump. For the next step, a miniaturized pivot bearing centrifugal blood pump PI-601 has been developed for use as a permanently implantable device after design optimization. The evolution from C1E3 to the PI-601 converts this pivot bearing centrifugal pump as a totally implantable centrifugal pump. A pivot bearing centrifugal pump will become an ideal assist pump for the patients with failing heart.
Collapse
Affiliation(s)
- T. Nakazawa
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - Y. Ohara
- Department of Thoracic and Cardiovascular Surgery, Nagoya University School of Medicine, Nagoya - Japan
| | - R. Benkowski
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - K. Makinouchi
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - Y. Takami
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - S. Ohtsubo
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - K. Kawahito
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - K. Tasai
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - J. Glueck
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - G.P. Noon
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - A. Sueoka
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| | - H. Schmallegger
- Univ. of Vienna, Boltzman Inst. for Cardiosurgical Research, Vienna - Austria
| | - H. Schima
- Univ. of Vienna, Boltzman Inst. for Cardiosurgical Research, Vienna - Austria
| | - E. Wolner
- Univ. of Vienna, Boltzman Inst. for Cardiosurgical Research, Vienna - Austria
| | - Y. Nosé
- Department of Surgery, Baylor College of Medicine, Houston, Texas - USA
| |
Collapse
|
4
|
Affiliation(s)
- K Sawada
- Department of Artificial Organs/L14, Cleveland Clinic Foundation, Ohio
| | | | | |
Collapse
|
5
|
Nishimura I, Ichikawa S, Mikami M, Ishitoya H, Motomura T, Kawamura M, Linneweber J, Glueck J, Shinohara T, Nosé Y. Evaluation of floating impeller phenomena in a Gyro centrifugal pump. Biomed Mater Eng 2013; 23:49-55. [PMID: 23442236 DOI: 10.3233/bme-120731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The Gyro centrifugal pump developed as a totally implantable artificial heart was designed with a free impeller, in which the rotational shaft (male bearing) of the impeller was completely separated from the female bearing. For this type of pump, it is very important to keep the proper magnet balance (impeller-magnet and actuator-magnet) in order to prevent thrombus formation and/or bearing wear. When the magnet balance is not proper, the impeller is jerked down into the bottom bearing. On the other hand, if magnet balance is proper, the impeller lifted off the bottom of the pump housing within a certain range of pumping conditions. In this study, this floating phenomenon was investigated in detail. The floating phenomenon was proved by observation of the impeller behavior using a transparent acrylic pump. The impeller floating phenomenon was mapped on a pump performance curve. The impeller floating phenomenon is affected by the magnet-magnet coupling distance and rotational speed of the impeller. In order to keep the proper magnet balance and to maintain the impeller floating phenomenon at the driving condition of right and left pump, the magnet-magnet coupling distance was altered by a spacer which was installed between the pump and actuator. It became clear that the same pump could handle different conditions (right and left ventricular assist), by just changing the thickness of the spacer. When magnet balance is proper, the floating impeller phenomenon occurs automatically in response to the impeller rev. It is called "the dynamic RPM suspension".
Collapse
Affiliation(s)
- Ikuya Nishimura
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Blumenstein M, Asanuma Y, Habersetzer R, Malchesky P, Samtleben W, Gurland H, Nosé Y. Kontinuierliche Kryofiltration von Plasma bei rheumatoider Arthritis*. AKTUEL RHEUMATOL 2008. [DOI: 10.1055/s-2008-1051098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
Linneweber J, Nonaka K, Ichikawa S, Ishitoya H, Motomura T, Nosé Y. Current status on the development of a totally implantable biventricular assist device: the Baylor Gyro BVAD. Thorac Cardiovasc Surg 2004; 52:1-5. [PMID: 15002068 DOI: 10.1055/s-2004-815796] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVE The Baylor Gyro BVAD is under development with the final goal of establishing a totally implantable biventricular assist system (BVAD). The aim of this study was to evaluate the safety, reliability, and effectiveness of the device in a long-term in vivo model. METHODS The BVAD was implanted into eight calves for longer than 4 weeks in a biventricular bypass fashion, with the native heart remaining. Pump performance was assessed with the system's digital data acquisition unit. Postoperatively, anticoagulation was maintained with i.v. heparin perfusion (ACT< or = 250 sec) gradually replaced by coumadin. Treadmill exercise tests were performed daily following a 10-day reconvalescence period after surgery. RESULTS The animals were kept alive for 37-90 days. The pumps yielded average flows of 5.3 +/- 1.1 l/min and 4.9 +/- 0.7 l/min for the LVAD and RVAD, respectively. Power consumption was 8.2 +/- 2.7 W and 9.6 +/- 4.7 W at 1935 +/- 123 rpm and 2015 +/- 365 rpm, respectively. All cases exhibited low hemolysis; renal and liver function were kept normal throughout the experiments. The animals demonstrated no thromboembolic neurological symptoms and tolerated moderate treadmill exercise. CONCLUSION The Baylor Gyro BVAD demonstrated effective and reliable in vivo performance with acceptable biocompatibility. Based on these studies, we conclude that the system will be suitable as a long-term totally implantable BVAD for uses intended for longer than two years.
Collapse
Affiliation(s)
- J Linneweber
- Klinik für kardiovaskuläre Chirurgie, Universitätsklinikum Charité der Humboldt-Universität zu Berlin, Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
8
|
Nishimura I, Ichikawa S, Mikami M, Ishitoya H, Motomura T, Kawamura M, Linneweber J, Glueck J, Shinohara T, Nosé Y, Nishimura I. Evaluation of floating impeller phenomena in a gyro centrifugal pump. ASAIO J 2004; 49:744-7. [PMID: 14655746 DOI: 10.1097/01.mat.0000093962.97611.01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
The Gyro centrifugal pump, developed as a totally implantable artificial heart, was designed with a free impeller in which the rotational shaft (male bearing) of the impeller was completely separated from the female bearing. For this type of pump, it is very important to keep the proper magnet balance (impeller-magnet and actuator-magnet balance) to prevent thrombus formation or bearing wear. When the magnet balance is not proper, the impeller is jerked down into the bottom bearing. On the other hand, if magnet balance is proper, the impeller is lifted off the bottom of the pump housing within a certain range of pumping conditions. In this study, this floating phenomenon was investigated in detail. The floating phenomenon was proven by observation of the impeller behavior by means of a transparent acrylic pump. The impeller floating phenomenon was mapped on a pump performance curve. The impeller floating phenomenon is affected by the magnet-magnet coupling distance and the rotational speed of the impeller. To keep the proper magnet balance and to maintain the impeller floating phenomenon at the driving conditions of right and left pumps, the magnet-magnet coupling distance was altered by a spacer that was installed between the pump and actuator. It became clear that the same pump could handle different conditions (right and left ventricular assist) by changing the thickness of the spacer. When magnet balance is proper, the floating impeller phenomenon occurs automatically in response to the impeller revolution. This is called "the dynamic revolutions per minute suspension."
Collapse
Affiliation(s)
- I Nishimura
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Nosé Y. Advancement in dialytic technologies: where to go? Artif Cells Blood Substit Immobil Biotechnol 2003; 31:149-50. [PMID: 12751834 DOI: 10.1081/bio-120020172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- Y Nosé
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA.
| |
Collapse
|
10
|
Affiliation(s)
- Y. Nosé
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio, U.S.A
| | - P.S. Malchesky
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio, U.S.A
| |
Collapse
|
11
|
Affiliation(s)
- P.S. Malchesky
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio 44106
| | - A. Sueoka
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio 44106
| | - S. Matsubara
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio 44106
| | - J. Wojcicki
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio 44106
| | - Y. Nosé
- Department of Artificial Organs, Cleveland Clinic Foundation, Cleveland, Ohio 44106
| |
Collapse
|
12
|
Linneweber J, Nonaka K, Takano T, Kawahito S, Schulte-Eistrup S, Motomura T, Ichikawa S, Mikami M, Stevens S, Schima H, Wolner E, Nosé Y. Hemodynamic exercise response in calves with an implantable biventricular centrifugal blood pump. Artif Organs 2001; 25:1018-21. [PMID: 11843772 DOI: 10.1046/j.1525-1594.2001.06788.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
An implantable biventricular assist device (BVAD) has been developed at Baylor College of Medicine using 2 centrifugal blood pumps. The aim of this study was to investigate the exercise-reflex response during nonpulsatile biventricular assistance and to evaluate to which degree the autoregulation of the system would accommodate the changed hemodynamic situation during physical exercise. The Baylor Gyro PI 710 BVAD has been implanted into 2 calves (strain half-Dexter) in a biventricular bypass fashion with native heart remaining. Allowing a 10 day convalescence, 2 animals were subjected to incremental exercise tests. The speed of the treadmill was increased at zero slope from 0.7 mph to 1.5 mph with increments of 0.2 mph every 3 min. During the exercise the pump flows were maintained at a fixed rate (6.93 +/- 0.01 L/min for the left ventricular assist device and 5.36 +/- 1.44 L/min for the right ventricular assist device). Hemodynamic parameters and pump performance were recorded continuously. The cardiac output (CO) and heart rate (HR) increased significantly during the exercise. CO increased from 11.1 +/- 0.3 to 13.1 +/- 0.4 L/min, and HR increased from 99 +/- 7.1 to 114 +/- 2.8 bpm, respectively. Mean aortic pressure, central venous pressure, and left arterial pressure did not change significantly. Also, no change was observed for the left and right pump flows. This totally implantable BVAD showed excellent long-term performance without any mechanical problems. It is feasible to operate without impairment under physical activity. However, the natural heart dominated the hemodynamic response during exercise under BVAD support. The left and the right pump flows did not increase spontaneously with exercise. We therefore conclude that a servo CO control system is necessary to regulate pump flows even during moderate exercise.
Collapse
Affiliation(s)
- J Linneweber
- Department of Cardiovascular Surgery, University Hospital Charité, Humboldt University, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
A hybrid hepatic assist device using canine liver tissues was developed and clinically applied 38 years ago. However, for many years practical hybrid hepatic assist devices were not clinically introduced owing to the many difficulties encountered in employing cultured hepatocytes. These problems include: (1) maintenance of viable cultured cells, (2) maintenance of normal hepatocyte function with these cells, (3) elimination of toxic substances generated by non-viable cultured and/or stored cells, (4) elimination of immunological factors generated by cultured cells and by the patient, and (5) difficulties of the biocompatible immunological barrier for cells against the patient. Fortunately, recent progress in apheresis and biomaterial technologies enable us to isolate cultured cells immunologically and yet maintain effective metabolic functions for the patient. These technologies generate an immunological barrier of a hybrid hepatic assist device for the patients. Proper adsorption columns developed for apheresis procedures enable us to remove the toxic substances released by non-viable cells. Recent development of oxygen-carrying macromolecules enable us to provide sufficient oxygen supply to the cultured cells and to maintain their normal cellular function, not only during the cultured period of time, but also during their actual clinical application. Together with the advancement of cell culture technologies, including the proper cultured environments and cellular seeding environments, these technologies, primarily developed for therapeutic apheresis, should be able to provide more effective and safe hybrid artificial organs.
Collapse
Affiliation(s)
- Y Nosé
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA.
| |
Collapse
|
14
|
Nonaka K, Linneweber J, Ichikawa S, Yoshikawa M, Kawahito S, Mikami M, Motomura T, Ishitoya H, Nishimura I, Oestmann D, Glueck J, Schima H, Wolner E, Shinohara T, Nosé Y. Development of the Baylor Gyro permanently implantable centrifugal blood pump as a biventricular assist device. Artif Organs 2001; 25:675-82. [PMID: 11722341 DOI: 10.1046/j.1525-1594.2001.06855.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The Baylor Gyro permanently implantable centrifugal blood pump (Gyro PI pump) has been under development since 1995 at Baylor College of Medicine. Excellent results were achieved as a left ventricular assist device (LVAD) with survival up to 284 days. Based on these results, we are now focusing on the development of a biventricular assist device (BVAD) system, which requires 2 pumps to be implanted simultaneously in the preperitoneal space. Our hypothesis was that the Gyro PI pump would be an appropriate device for an implantable BVAD system. The Gyro PI 700 pump is fabricated from titanium alloy and has a 25 ml priming volume, pump weight of 204 g, height of 45 mm, and pump diameter of 65 mm. This pump can provide 5 L/min against 100 mm Hg at 2,000 rpm. In this study, 6 half-Dexter healthy calves have been used as the experimental model. The right pump was applied between the infundibular of the right ventricle and the main pulmonary artery. The left pump was applied between the apex of the left ventricle and the thoracic descending aorta. As for anticoagulation, heparin was administered at the first postoperative week and then converted to warfarin sodium from the second week after surgery. Both pump flow rates were controlled maintaining a pulmonary arterial flow of less than 160 ml/kg/min for the sake of avoidance of pulmonary congestion. Blood sampling was done to assess visceral organ function, and the data regarding pump performance were collected. After encountering the endpoint, which the study could not keep for any reasons, necropsy and histopathological examinations were performed. The first 2 cases were terminated within 1 week. Deterioration of the pump flow due to suction phenomenon was recognized in both cases. To avoid the suction phenomenon, a flexible conduit attached on the inlet conduit was designed and implanted. After using the flexible inflow conduit, the required power and the rotational speed were reduced. Furthermore, the suction phenomenon was not observed except for 1 case. There was no deterioration regarding visceral organ function, and pulmonary function was maintained within normal range except for 1 case. Even though the experimental animal survived up to 45 days with the flexible inflow conduit, an increase in power consumption due to thrombus formation behind the impeller became a problem. Lower rotational speed, which was probably produced by the effectiveness of the flexible inflow conduit, was speculated to be one of the reasons. And the minimum range of rotational speed was 1,950 rpm in these 6 BVAD cases and the previous 3 cases of LVAD. In conclusion, 6 cases of BVAD implantation were performed as in vivo animal studies and were observed up to 45 days. The flexible inflow conduit was applied in 4 of 6 cases, and it was effective in avoiding a suction phenomenon. The proper rotational speed of the Gyro PI 700 pump was detected from the viewpoint of antithrombogenicity, which is more than 1,950 rpm.
Collapse
Affiliation(s)
- K Nonaka
- Baylor College of Medicine, Michael E. DeBakey Department of Surgery, Houston, Texas, U.S.A.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Kawahito S, Maeda T, Yoshikawa M, Takano T, Nonaka K, Linneweber J, Mikami M, Motomura T, Ichikawa S, Glueck J, Nosé Y. Blood trauma induced by clinically accepted oxygenators. ASAIO J 2001; 47:492-5. [PMID: 11575824 DOI: 10.1097/00002480-200109000-00019] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Hemolysis remains one of the most serious problems during cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), and percutaneous cardiopulmonary support (PCPS). However, the hemolytic characteristics associated with oxygenators are not well defined. A specialized hemolysis test protocol for oxygenators was developed. A comparative study was performed following this protocol to determine the hemolytic characteristics of the clinically available oxygenators during CPB; pressure drop measurements in the blood chamber were also performed. Four oxygenators (Medtronic Affinity, Cobe Optima, Terumo Capiox SX25, and Bard Quantum) were evaluated. Fresh blood from healthy Dexter calves anticoagulated with citrate phosphate dextrose adenine solution was used. The blood flow was fixed at 5 L/min, similar to that used in CPB. The Normalized Index of Hemolysis for Oxygenators (NIHO) has been modified according to the American Society of Testing and Materials (ASTM) standards. The NIH value, which was obtained from the circuit without an oxygenator, was subtracted from the primary NIH value, obtained from the circuit with an oxygenator to eliminate the effects of a centrifugal pump or other artifacts. The NIHO value was the lowest in the Affinity (0.0116 +/- 0.0017) and increased from Affinity < Optima (0.0270 +/- 0.0038) < Capiox (0.0335 +/- 0.0028) < Quantum (0.0416 +/- 0.0015 g/100 L). The Optima and Capiox did not demonstrate a significant difference. In addition, this NIHO value has a close relationship to the pressure drop. In conclusion, this new evaluation method is suitable to compare the biocompatibility performance of different types of clinically available oxygenators for CPB usage.
Collapse
Affiliation(s)
- S Kawahito
- Baylor College of Medicine, Michael E. DeBakey Department of Surgery, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Linneweber J, Chow TW, Takano T, Maeda T, Nonaka K, Schulte-Eistrup S, Kawahito S, Elert O, Moake JL, Nosé Y. Direct detection of red blood cell fragments: a new flow cytometric method to evaluate hemolysis in blood pumps. ASAIO J 2001; 47:533-6. [PMID: 11575832 DOI: 10.1097/00002480-200109000-00027] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Pump induced hemolysis is presently evaluated by measuring plasma free hemoglobin (fHb). However, this method has disadvantages because quantification of fHb depends on hematocrit (HCT) and hemoglobin (Hb) levels. The aim of this work was to devise a hemoglobin independent method, capable of quantifying cell trauma directly by measuring the number of red blood cell (RBC) fragments. Whole blood flow cytometry was used to quantify circulating RBC fragments derived from a roller pump (Sarns, Inc. Model 2 M 6,002) and a centrifugal pump (Gyro C1E3, Kyocera Corp.). The pumps were tested in a mock circuit for 2 hr (5 L/min flow against 100 mm Hg pressure head). Red blood cell fragments were quantified by a phycoerythrin (PE) labeled glycophorin A antibody specific for erythrocytes. Red blood cell fragments were smaller than the intact RBC population and overlapped in size with the platelet population (based on forward- and side-light scattering measurements). For the roller pump, the values for RBC fragments increased from 1,090 +/- 260/microl at 0 min to 14,880 +/- 5,900/microl after 120 min. In contrast, using the centrifugal pump, there was little increase in RBC fragments (from 730 +/- 270/microl at 0 min to 1,400 +/- 840/microl after 120 min). Flow cytometry can be used for the rapid, sensitive, hemoglobin independent evaluation of pump induced RBC trauma.
Collapse
Affiliation(s)
- J Linneweber
- Baylor College of Medicine, Department of Surgery, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Affiliation(s)
- K Hanazaki
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | |
Collapse
|
18
|
Kawahito S, Maeda T, Motomura T, Takano T, Nonaka K, Linneweber J, Mikami M, Ichikawa S, Kawamura M, Glueck J, Sato K, Nosé Y. Development of a new hollow fiber silicone membrane oxygenator: in vitro study. Artif Organs 2001; 25:494-8. [PMID: 11453882 DOI: 10.1046/j.1525-1594.2001.06706-3.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
An experimental silicone hollow fiber membrane oxygenator for long-term extracorporeal membrane oxygenation (ECMO) was developed in our laboratory using an ultrathin silicone hollow fiber. However, the marginal gas transfer performances and a high-pressure drop in some cases were demonstrated in the initial models. In order to improve performance the following features were incorporated in the most recent oxygenator model: increasing the fiber length and total surface area, decreasing the packing density, and modifying the flow distributor. The aim of this study was to evaluate the gas transfer performances and biocompatibility of this newly improved model with in vitro experiments. According to the established method in our laboratory, in vitro studies were performed using fresh bovine blood. Gas transfer performance tests were performed at a blood flow rate of 0.5 to 6 L/min and a V/Q ratio (V = gas flow rate, Q = blood flow rate) of 2 and 3. Hemolysis tests were performed at a blood flow rate of 1 and 5 L/min. Blood pressure drop was also measured. At a blood flow rate of 1 L/min and V/Q = 3, the O2 and CO2 gas transfer rates were 72.45 +/- 1.24 and 39.87 +/- 2.92 ml/min, respectively. At a blood flow rate of 2 L/min and V/Q = 3, the O2 and CO2 gas transfer rates were 128.83 +/- 1.09 and 47.49 +/- 5.11 ml/min. Clearly, these data were superior to those obtained with previous models. As for the pressure drop and hemolytic performance, remarkable improvements were also demonstrated. These data indicate that this newly improved oxygenator is superior to the previous model and may be clinically acceptable for long-term ECMO application.
Collapse
Affiliation(s)
- S Kawahito
- Baylor College of Medicine, Michael E. DeBakey Department of Surgery, Houston, Texas, U.S.A.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Kawahito S, Maeda T, Takano T, Nonaka K, Linneweber J, Mikami M, Motomura T, Ichikawa S, Glueck J, Sato K, Kuwana J, Nosé Y. Gas transfer performance of a hollow fiber silicone membrane oxygenator: ex vivo study. Artif Organs 2001; 25:498-502. [PMID: 11453883 DOI: 10.1046/j.1525-1594.2001.06706-4.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Based on the results of in vitro studies of many experimental models, a silicone hollow fiber membrane oxygenator for pediatric cardiopulmonary bypass (CPB) and extracorporeal membrane oxygenation (ECMO) was developed using an ultrathin silicone hollow fiber with a 300 microm outer diameter and a wall thickness of 50 microm. In this study, we evaluated the gas transfer performance of this oxygenator simulating pediatric CPB and ECMO conditions. Two ex vivo studies in a pediatric CPB condition for 6 h and 5 ex vivo studies in an ECMO condition for 1 week were performed with venoarterial bypass using healthy calves. At a blood flow rate of 2 L/min and V/Q = 4 (V = gas flow rate, Q = blood flow rate) (pediatric CPB condition), the O2 and CO2 gas transfer rates were maintained at 97.44 +/- 8.88 (mean +/- SD) and 43.59 +/- 15.75 ml/min/m2, respectively. At a blood flow rate of 1 L/min and V/Q = 4 (ECMO condition), the O2 and CO2 gas transfer rates were maintained at 56.15 +/- 8.49 and 42.47 +/- 9.22 ml/min/m2, respectively. These data suggest that this preclinical silicone membrane hollow fiber oxygenator may be acceptable for both pediatric CPB and long-term ECMO use.
Collapse
Affiliation(s)
- S Kawahito
- Baylor College of Medicine, Michael E. DeBakey Department of Surgery, Houston, Texas, U.S.A.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
|
21
|
Kawahito S, Takano T, Nakata K, Maeda T, Nonaka K, Linneweber J, Schulte-Eistrup S, Sato T, Mikami M, Glueck J, Nosé Y. Analysis of the arterial blood pressure waveform during left ventricular nonpulsatile assistance in animal models. Artif Organs 2000; 24:816-20. [PMID: 11091171 DOI: 10.1046/j.1525-1594.2000.06646.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
When the rotary blood pump is used as a left ventricular assist device (LVAD), the arterial blood pressure waveform changes with the LVAD condition. Based on evidence from an in vitro study, the change of the arterial blood pressure waveform during left ventricular assistance was evaluated using animal models. After the left pleural cavity was opened through the fifth intercostal space under general anesthesia, a rotary blood pump was implanted as an LVAD into 6 healthy calves. The direct left carotid arterial blood pressure waveform was measured and recorded by an oscilloscope. The Fast Fourier Transform technique was utilized to analyze the arterial blood pressure waveform and calculate the pulsatility index (PI) and the pulse power index (PPI). Similar to the in vitro study, the PI and PPI decreased exponentially with the increase of the LVAD assist ratio. By using this analysis methodology, a physiologically effective ventricular assistance might be achieved.
Collapse
Affiliation(s)
- S Kawahito
- Baylor College of Medicine, Department of Surgery, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Takano T, Schulte-Eistrup S, Yoshikawa M, Nakata K, Kawahito S, Maeda T, Nonaka K, Linneweber J, Glueck J, Fujisawa A, Makinouchi K, Yokokawa M, Nosé Y. Impeller design for a miniaturized centrifugal blood pump. Artif Organs 2000; 24:821-5. [PMID: 11091172 DOI: 10.1046/j.1525-1594.2000.06630.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The impeller design for a miniature centrifugal blood pump is an important consideration since the small diameter impeller requires higher rotational speed, which may cause more blood trauma compared to the larger diameter impeller. Three different impeller vanes (straight vanes with a height of 4 mm and 8 mm, and 8 mm curved vanes) of which the diameter was 35 mm were subjected to hydraulic performance and hemolysis tests in the same pump housing. Both straight vane impellers attained left ventricular assist condition (5 L/min against 100 mm Hg) at 2,900 rpm while the curved vane required 3,280 rpm. There was no significant hemolysis difference between the tall and short vanes. The curved impeller vanes did not exhibit sufficient hydraulic performance when compared to the straight vanes. The straight vane impellers, even with different heights, were incorporated into the same pump housings, and the vane heights did not drastically change the hydraulic performance or hemolysis.
Collapse
Affiliation(s)
- T Takano
- Baylor College of Medicine, Department of Surgery, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Nakata K, Yoshikawa M, Takano T, Maeda T, Nonaka K, Linneweber J, Kawahito S, Glueck J, Fujisawa A, Makinouchi K, Yokokawa M, Nosé Y. Gyro pump wear and deformation analysis in vivo study: creep deformation. Artif Organs 2000; 24:653-5. [PMID: 10971256 DOI: 10.1046/j.1525-1594.2000.06596.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The Gyro pump has a double pivot bearing system to support its impeller. In this study, the integrity of the bearing system was examined after ex vivo studies. The pumps were implanted into calves and evaluated for different periods as a paracorporeal left ventricular assist device (LVAD). One pump was subjected to a test of 30 days, 1 for 15 days, 4 for 14 days, 1 for 10 days, 1 for 7 days, 2 for 4 days, and 4 for 2 days. One additional pump was subjected to percutaneous cardiopulmonary support (PCPS) condition for 6 days (total pressure head 500 mm Hg with a pump flow rate of 3 L/min). The anticoagulation treatment consisted of a continuous administration of heparin to maintain an achieved clotting time (ACT) of 200-250 s during the LVAD study and 250-300 s during the PCPS study. After the experiment, the pumps were disassembled, and the wear and deformation of male and female bearings were analyzed. There were no dimensional changes on male bearings but there were on female bearings. Wear and deformation of the female bearings were calculated as follows: wear and deformation = (depth of female before pumping) - (depth after pumping). Thirteen assembled Gyro pumps were disassembled to measure the depth of the female bearings before pumping. There was no statistical relationship between the wear and deformation and the motor speed x driving period. From these results, the deformation was not due to wear but to the creep or elastic deformation. This study suggested that the double pivot bearing system of the Gyro pump is highly durable.
Collapse
Affiliation(s)
- K Nakata
- Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Yoshikawa M, Nakata KI, Nonaka K, Linneweber J, Kawahito S, Takano T, Shulte-Eistrup S, Maeda T, Glueck J, Schima H, Wolner E, Nosé Y. Right ventricular assist system feedback flow control parameter for a rotary blood pump. Artif Organs 2000; 24:659-66. [PMID: 10971258 DOI: 10.1046/j.1525-1594.2000.06579.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
At least 25-30% of patients with a permanent implantable left ventricular assist device (LVAD) experience right ventricular failure; therefore, an implantable biventricular assist system (BiVAS) with small centrifugal pumps is being developed. Many institutions are focusing and developing a control system for a left ventricular assist system (LVAS) with rotary blood pumps. These authors feel that the right ventricular assist system (RVAS) with rotary blood pumps should be developed simultaneously. A literature search indicated no recent reports on the effect of hemodynamics and exercise with this type of nonpulsatile implantable RVAS. In this study, a calf with an implantable right ventricular assist system (RVAS) was subjected to 30 min of exercise on a treadmill at 1.5 mph, resulting in excellent hemodynamics. The input voltage remained unchanged. Hemodynamic recordings were taken every 5 min throughout the testing period, and blood gas analysis was done every 10 min. Oxygen uptake (VO2), oxygen delivery (DO2), and oxygen extraction (O2ER) were calculated and analyzed. Two different pump flows were investigated: Group 1 low assist (<3.5 L/min) and Group 2 high assist (>3.5 L/min). In both groups, the RVAS flow rates were unchanged while the pulmonary artery (PA) flow increased during exercise; also, the heart rate and right atrial pressure (RAP) increased during exercise. There were no significant differences in the 2 groups. The PA flow correlates to the heart rate during exercise. In all of the tests, the VO2 and DO2 increased during exercise. Regarding VO2, no changes were observed during the different flow conditions; however, the DO2 of Group 2 was higher than that of Group 1. Because the implantable RVAS did not have pump flow changes during the test conditions, it was necessary to incorporate a flow control system for the implantable RVAS. During exercise with an implantable RVAS rotary blood pump, incorporating the heart rate and VO2 as feedback parameters is feasible for controlling the flow rate.
Collapse
Affiliation(s)
- M Yoshikawa
- Baylor College of Medicine, Houston, Texas, USA; and University of Vienna, Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Nakata K, Yoshikawa M, Takano T, Maeda T, Nonaka K, Linneweber J, Kawahito S, Glueck J, Fujisawa A, Makinouchi K, Yokokawa M, Nosé Y. Antithrombogenicity evaluation of a centrifugal blood pump. Artif Organs 2000; 24:667-70. [PMID: 10971259 DOI: 10.1046/j.1525-1594.2000.06610.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The Gyro C1E3 pump was developed not only for cardiopulmonary bypass but also as a short-term assist device. The main purpose of this study was to examine the correlation between the thrombus formation factor and the Gyro C1E3 pumps. Seven pumps were implanted into 3 calves and evaluated for different periods of duration as a paracorporeal left ventricular assist device (LVAD). One pump was subjected to percutaneous cardiopulmonary support condition (PCPS) (total pressure head 500 mm Hg with a pump flow rate of 3 L/min). The anticoagulation treatment consisted of a continuous administration of heparin to maintain an activated clotting time (ACT) of 200-250 during the LVAD study and 250-300 during the PCPS study. After the experiment, the pumps were disassembled and examined. In cases where there were any blood-derived deposits inside the pumps, the dry weight of these thrombi that adhered to the bearing area of the pump was measured. A multiple correlation was attempted to speculate possible thrombus formation. The estimated dry weight of thrombi was calculated from pump flow rate, pumping day, motor speed, and activated clotting time. This equation was estimated dry weight of thrombi = 1.140 x pump flow rate -0.001 motor speed + 1.652 pumping time -0.041 x ACT + 2.198 R2 = 0.944. This study suggested that there was a possibility to calculate the amount of adhered thrombus formation from pump flow rate, motor speed, pumping day, and ACT.
Collapse
Affiliation(s)
- K Nakata
- Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Kawahito S, Nakata K, Nonaka K, Sato T, Yoshikawa M, Takano T, Maeda T, Linneweber J, Schulte-Eistrup S, Flowers D, Glueck J, Nosé Y. Analysis of the arterial blood pressure waveform using Fast Fourier Transform technique during left ventricular nonpulsatile assistance: in vitro study. Artif Organs 2000; 24:580-3. [PMID: 10916071 DOI: 10.1046/j.1525-1594.2000.06502-3.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The arterial blood pressure waveform is variable during left ventricular assistance. The aim of this study is to examine the correlation between the left ventricular assist device (LVAD) condition and the arterial blood pressure waveform in a fixed cardiac output condition using a mock circuit. This mock circulation loop was composed of an aortic compliance chamber, a left atrial compliance chamber, a pneumatic pulsatile pump as a native heart, and a rotary blood pump representing the LVAD with left atrial drainage. The Fast Fourier Transform technique was utilized to analyze the arterial blood pressure waveform and calculate the pulsatility index (PI) and the pulse power index (PPI). The PI and PPI decreased with the increase of the LVAD rotational speed, exponentially. There was a significant negative correlation between the PI, PPI, and the LVAD rotational speed, flow rate, and assist ratio. The best correlation was observed between the PPI and the assist ratio (r = 0.986). From this viewpoint, an ideal LVAD condition may be estimated from the pulsatility change of the arterial blood pressure waveform.
Collapse
Affiliation(s)
- S Kawahito
- Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Maeda T, Iwasaki A, Kawahito S, Nakata K, Nonaka K, Linneweber J, Schulte-Eistrup S, Takano T, Yoshikawa M, Sato K, Kuwana J, Murabayashi S, Nosé Y. Preclinical evaluation of a hollow fiber silicone membrane oxygenator for extracorporeal membrane oxygenator application. ASAIO J 2000; 46:426-30. [PMID: 10926139 DOI: 10.1097/00002480-200007000-00011] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
A silicone membrane hollow fiber oxygenator applicable for use as an extracorporeal membrane oxygenator (ECMO) has been developed in our laboratory. This silicone hollow fiber displays astonishing mechanical stability, is barely compressible or stretchable, and assembles easily while maintaining good gas permeability. The priming volume is 140 cc with a surface area of 0.8 m2. This study evaluated the gas transfer performances and biocompatibility of the oxygenator under ECMO and CPB conditions. In vitro studies that were performed at a blood flow rate of 2 L/min, and revealed O2 and CO2 gas transfer rates of 82.35 +/- 0.56 ml/m2/L/min and 38.72 +/- 2.88 ml/m2/L/min, respectively. The commercially available Kolobow (Avecor 1500) oxygenator was used as the control, and had O2 and CO2 gas transfer rates of 53.8 +/- 0.5 ml/m2/L/min and 24.7 +/- 2.0 ml/m2/L/min. To evaluate blood trauma, Normalized Index of Hemolysis (NIH) was measured according to American Society of Testing and Materials (ASTM) standards. The NIH findings were 0.0112 g/100L at a blood flow of 1 L/min, and 0.0152 g/100L at 5 L/min. Three ex vivo experiments, using a blood flow rate of 1 L/min, were performed with venoarterial bypass, and O2 transfer rate and CO2 transfer rate of the oxygenators were well maintained. This indicates that this preclinical silicone membrane hollow fiber oxygenator has superior efficiency, less blood trauma, and is smaller when compared with the only clinically available Kolobow oxygenator.
Collapse
Affiliation(s)
- T Maeda
- Baylor College of Medicine, Department of Surgery, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Yoshikawa M, Nonaka K, Linneweber J, Kawahito S, Ohtsuka G, Nakata K, Takano T, Schulte-Eistrup S, Glueck J, Schima H, Wolner E, Nosé Y. Development of the NEDO implantable ventricular assist device with Gyro centrifugal pump. Artif Organs 2000; 24:459-67. [PMID: 10886066 DOI: 10.1046/j.1525-1594.2000.06595.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The Gyro centrifugal pump, PI (permanently implantable) series, is being developed as a totally implantable artificial heart. Our final goal is to establish a "functional TAH," a totally implantable biventricular assist system (BiVAS) with centrifugal pumps. A plastic prototype pump, Gyro PI 601, was evaluated through in vitro and in vivo studies as a single ventricular assist device (VAD). Based upon these results, the pump head material was converted to a titanium alloy, and the actuator was modified. These titanium Gyro pumps, PI 700 series, also were subjected to in vitro and in vivo studies. The Gyro PI 601 and PI 700 series have the same inner dimensions and characteristics, such as the eccentric inlet port, double pivot bearing system, secondary vane, and magnet coupling system; however, the material of the PI 700 is different from the PI 601. The Gyro PI series is driven by the Vienna DC brushless motor actuator. The inlet cannula of the right ventricular assist system (RVAS) specially made for this system consists of 2 parts: a hat-shaped silicone tip biolized with gelatin and an angled wire reinforced tube made of polyvinylchloride. The pump-actuator package was implanted into 8 calves in the preperitoneal space, bypassing from the left ventricle apex to the descending aorta for the left ventricular assist system (LVAS) and bypassing the right ventricle to the main pulmonary artery for the RVAS. According to the PI 601 feasibility protocol, 2 LVAS cases were terminated after 2 weeks, and 1 LVAS case and 1 RVAS were terminated after 1 month. The PI 700 series was implanted into 4 cases: 3 LVAS cases survived for a long term, 2 of them over 200 days (72-283 days), and 1 RVAS case survived for 1 month and was terminated according to the protocol for a short-term antithrombogenic screening and system feasibility study. Regarding power consumption, the plastic pump cases demonstrated from 6.2 to 12.1 W as LVAS and 7.3 W as RVAS, the titanium pump cases showed from 10.4 to 14.2 W as LVAS and 15.8 W as RVAS. All cases exhibited low hemolysis. The renal function and the liver function were maintained normally in all cases throughout these experimental periods. In the 2 RVAS cases, pulmonary function was normally maintained. No calves demonstrated thromboembolic signs or symptoms throughout the experiments except Case 1 with the plastic pump. However, in the plastic pump cases, bilateral renal infarction was suspected in 2 cases during necropsy whereas no abnormal findings were revealed in the titanium pump cases. There were also no blood clots inside the PI 700 series. As for the 601, the explanted pumps demonstrated slight thrombus formations at the top and bottom pivots except in 1 case. The Gyro PI series, especially the PI 700 series, demonstrated superior performance, biocompatibility, antithrombogenicity and low hemolysis. Also, the durability of the actuator was demonstrated. Based on these results, this titanium centrifugal pump is suitable as an implantable LVAS and RVAS. It is likely that the Gyro PI series is a feasible component of the BiVAS functional TAH.
Collapse
Affiliation(s)
- M Yoshikawa
- Baylor College of Medicine, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
Even though clinical acceptance of a nonpulsatile blood flow was demonstrated almost 45 years ago, the development of a nonpulsatile blood pump was completely ignored until 20 years ago. In 1979, the first author's group demonstrated that completely pulseless animals did not exhibit any abnormal physiology if 20% higher blood flows were provided to them. However, during the next 10 years (1979-1988), minimum efforts were provided for the development of a nonpulsatile, permanently implantable cardiac prosthesis. In 1989, the first author and his team at Baylor College of Medicine initiated a developmental strategy of various types of nonpulsatile rotary blood pumps, including a 2-day rotary blood pump for cardiopulmonary bypass application, a 2 week pump for ECMO and short-term circulatory assistance, a 2 year pump as a bridge to transplantation, and a permanently implantable cardiac prosthesis. Following the design and developmental strategy established in 1989, successful development of a 2-day pump (the Nikkiso-Fairway cardiopulmonary bypass pump) in 4 years (1989-1993), a 2 week pump (Kyocera gyro G1E3 pump) in 6 years (1992-1998), and a bridge to transplant pump (DeBakey LVAD-an axial flow blood pump) in 10 years (1988-1998) was made. Currently, a permanently implantable centrifugal blood pump development program is successfully completing its initial Phase 1 program of 5 years (1995-2000). Implantation exceeded 9 months without any negative findings. An additional 5 year Phase II program (2000-2005) is expected to complete such a device that will be clinically available.
Collapse
Affiliation(s)
- Y Nosé
- Department of Surgery, Baylor College of Medicine, Houston, Texas 77040, USA
| | | | | | | |
Collapse
|
30
|
Takano T, Nakata K, Schulte-Eistrup S, Kawahito S, Glueck J, Clarke IC, Williams PA, Maeda T, Nonaka K, Linneweber J, Yoshikawa M, Fujisawa A, Makinouchi K, Yokokawa M, Nosé Y. Particles released from the Gyro C1E3 during simulated extracorporeal circulation. Artif Organs 2000; 24:446-9. [PMID: 10886063 DOI: 10.1046/j.1525-1594.2000.06628.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Evaluation of released particles from the blood pump during extracorporeal circulation is an important aspect because the particles may cause microembolism. The Gyro C1E3 is a centrifugal blood pump that has an impeller suspended by double pivot bearings inside the housing; therefore, it is important to evaluate the released particles. The C1E3 was driven for 14 days to simulate clinical left ventricular assist device (LVAD) and percutaneous cardiopulmonary support (PCPS). Also, a roller pump was driven for 2 days as a comparison. Released particles were weighed and examined by SEM. After 14 days of pumping, the particles from the C1E3 were 238.6 microg in an LVAD condition. The particles with the roller pump were 270.2 microg after only 2 days. Average particle sizes with the roller pump and C1E3 were 3.7 and 0.6 microm, respectively. These results suggest that the Gyro C1E3 substantially reduces the risk of microembolism from released particles.
Collapse
Affiliation(s)
- T Takano
- Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Nosé Y. Develpment of cardiac protheses in Japan. Ann Thorac Cardiovasc Surg 2000; 6:143-5. [PMID: 11182925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
|
32
|
Yoshikawa M, Nakata K, Takano T, Maeda T, Glueck J, Murabayashi S, Schima H, Wolner E, Nosé Y. Development of an implantable small right ventricular assist device. ASAIO J 2000; 46:338-43. [PMID: 10826748 DOI: 10.1097/00002480-200005000-00019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Currently, at least two permanent implantable left ventricular assist devices (LVADs) are used clinically. Unfortunately, there is no small implantable right ventricular assist device (RVAD) available, even though at least 25-30% of this patient population has right ventricular failure. If a small implantable RVAD were available, biventricular assist could support patients with right ventricular failure. A small atraumatic and antithrombogenic RVAD is being developed to meet this clinical need. This small centrifugal blood pump, the Gyro PI pump, is 6.5 cm in diameter and 4.6 cm in height and has three unique characteristics to prevent thrombus formation: (1) the double pivot bearing and magnetic coupling system enable this pump to be completely sealless; (2) the secondary vanes at the bottom of the impeller accelerate the blood flow and prevent blood stagnation; and (3) the eccentric inlet port enables the top female bearing to be embedded into the top housing and decrease blood cell trauma. The inflow conduit consists of a wire reinforced tube and a hat-shaped tip that is biolized with gelatin to create a thrombus resistant material. This conduit is directly implanted into the right ventricle, and the outflow conduit is anastomosed to the PA. The pump can be implanted inside the abdominal wall or in the thoracic cavity. Biocompatibility of this pump was proved in two calves by thrombus free implantation as an LVAD for 284 days and 200 days. Two RVAD implantations were conducted, aiming for 1-month system feasibility studies. During the month, the RVADs operated satisfactorily without any thromboembolic incident. No blood clots or abnormal findings were seen inside the pump, nor were there abnormal findings in the explanted lungs except for small areas of atelectasis. The pump flow was 3.02 +/- 0.38 L/min in calf 1 and 3.75 +/- 1.18 L/min in calf 2. The power requirement was 7.28 +/- 0.43W for calf 1 and 14.52 +/- 3.93W for calf 2. The PaO2 was 72.0 +/- 3.60 mm Hg (calf 1) and 72.0 +/- 7.63 mm Hg (calf 2); PaCO2 was 38.3 +/- 2.17 mm Hg (calf 1) and 34.1 +/- 1.95 mm Hg (calf 2); and SaO2 was 94.1 +/- 1.37% (calf1) and 95.0 +/- 1.95% (calf 2). Gas exchange via the lungs was maintained. These studies indicate that the Gyro PI pump is suitable as a single implantable RVAD, and is a feasible RVAD as a part of a BiVAD system in terms of pump performance and thrombus resistance.
Collapse
Affiliation(s)
- M Yoshikawa
- Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Nakata K, Yoshikawa M, Takano T, Sankai Y, Ohtsuka G, Glueck J, Fujisawa A, Makinouchi K, Yokokawa M, Nosé Y. Estimation of pump flow rate and abnormal condition of implantable rotary blood pumps during long-term in vivo study. Artif Organs 2000; 24:315-9. [PMID: 10816208 DOI: 10.1046/j.1525-1594.2000.06534-4.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The control system for an implantable rotary blood pump is not clearly defined. A detection system is considered to be necessary for pump flow monitoring and abnormal conditions such as back flow or a sucking phenomenon where the septum or left ventricle wall is sucked into the cannula, etc. The ultrasound flowmeter is durable and reliable but the control system should not be totally dependent on the flowmeter. If the flowmeter breaks, the rotary blood pumps have no control mechanism. Therefore, the authors suggest controlling the pumps by an intrinsic parameter. One left ventricular assist device (LVAD) calf model was studied where the flow rate and waveform of the pump flow proved to identify the sucking phenomenon. Thus, the pump flow rate was calculated from the required power, motor speed, and heart rate. The value of the coefficient of determination (R2) between the measured and estimated pump flow rate was 0.796. To estimate this abnormal phenomenon, 2 methods were evaluated. One method was the total pressure head in which the pump flow rate and motor speed were estimated. During normal conditions the total pressure head is 79.5 +/- 7.0 mm Hg whereas in the abnormal condition, it is 180.0 +/- 2.8 mm Hg. There was a statistical difference (p < 0.01). Another method is using a current waveform. There is an association between the current and pump flow waves. The current was differentiated and squared to calculate the power of the differentiated current. The normal range of this value was 0.025 +/- 0.029; the abnormal condition was 11.25 +/- 15.13. There was a statistical difference (p < 0.01). The predicted flow estimation method and a sucking detection method were available from intrinsic parameters of the pump and need no sensors. These 2 methods are simple, yet effective and reliable control methods for a rotary blood pump.
Collapse
Affiliation(s)
- K Nakata
- Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Fukunaga K, Shimoyama T, Sawada K, Sueoka A, Nosé Y. Development of the membrane autotransfusion system prototype-II: MATS-II. Artif Organs 2000; 24:289-95. [PMID: 10816202 DOI: 10.1046/j.1525-1594.2000.06434.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
This article is the second of a two-part series describing a membrane autotransfusion system, MATS, utilizing plasmapheresis technology. Based on experiences obtained from the first prototype (MATS-I), optimum blood filtration parameters with refined blood and flux pump synchronization were put into an original CPU-board and loaded on a miniaturized, self-operative, and preclinical prototype (MATS-II). This study was conducted to evaluate the MATS-II using diluted blood of various hematocrit concentrations. The results proved that this device could concentrate 4,000-10,000 ml of various hematocrit concentrations into higher than 40% while automatically controlling the flow speed from 250 to 400 ml/min. Also, no significant damage was generated to the red blood cells (RBC). Moreover, the MATS-II salvaged over 90% of platelets together with the RBC. These results suggest that the MATS-II achieves all clinical requirements of an autotransfusion device; it is a continuous hemoconcentration device with minimum damage to cellular components of the blood.
Collapse
Affiliation(s)
- K Fukunaga
- Department of Internal Medicine IV, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | | | | | | | | |
Collapse
|
35
|
Murabayashi S, Omokawa S, Takaoka T, Malchesky PS, Nosé Y. Biocompatibility in membrane plasmapheresis: the necessity of global understanding. 1987. Ther Apher 2000; 4:173-82. [PMID: 10805438 DOI: 10.1046/j.1526-0968.2000.004002173.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
36
|
Malchesky PS, Sueoka A, Matsubara S, Wojcicki J, Nosé Y. Membrane plasma separation. 1983. Ther Apher 2000; 4:47-53. [PMID: 10728504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
|
37
|
Nosé Y, Horiuchi T, Malchesky PS, Smith JW, Matsubara S, Abe Y. Therapeutic cryogel removal in autoimmune disease: what is cryogel. 1982. Ther Apher 2000; 4:38-43. [PMID: 10728502 DOI: 10.1046/j.1526-0968.2000.00239.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
38
|
Nosé Y, Malchesky PS. Therapeutic membrane plasmapheresis. 1981. Ther Apher 2000; 4:3-9. [PMID: 10728495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
|
39
|
Sueoka A, Wojcicki J, Malchesky PS, Nosé Y. Polyvinylalcohol membranes for plasma separation. 1983. Ther Apher 2000; 4:58-64. [PMID: 10728506 DOI: 10.1046/j.1526-0968.2000.00241.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
40
|
Fukunaga K, Shimoyama T, Sawada K, Mueller J, Sueoka A, Nosé Y. In vitro evaluation study of the membrane autotransfusion system experimental prototype: MATS-I. Artif Organs 2000; 24:95-102. [PMID: 10718761 DOI: 10.1046/j.1525-1594.2000.06428.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Membrane Autotransfusion System (MATS) utilizing plasmapheresis technology has been developed in our laboratory. A specially designed polyethylene hollow fiber membrane was utilized. This study was conducted to evaluate performance of the first experimental prototype, MATS-I. The results of this study showed that the MATS-I could concentrate diluted blood at 10% of the initial hematocrit concentration (HCTi) into over 40% after passing through the system at a transmembrane pressure of 70 mm Hg. Moreover, the MATS-I can continuously treat 10,000 ml of diluted blood at various HCTi levels without deteriorating its performances. Even though the MATS-I met all required performances as an autotransfusion system, several areas of improvement of the system were necessary to meet various clinical needs. The next prototype, MATS-II, can be designed based on experiences obtained from the MATS-I. The MATS is smaller, more atraumatic and continuous, and is a faster system when compared to the currently available centrifugal autotransfusion devices.
Collapse
Affiliation(s)
- K Fukunaga
- Department of Internal Medicine IV, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
| | | | | | | | | | | |
Collapse
|
41
|
Nosé Y, Usami M, Malchesky PS, Emura M, Horiuchi T, Sakamoto H, Smith JW. Clinical thermofiltration: initial application. 1985. Ther Apher 2000; 4:44-6. [PMID: 10728503 DOI: 10.1046/j.1526-0968.2000.00240.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
42
|
Castino F, Scheucher K, Malchesky PS, Koshino I, Nosé Y. Microemboli-free blood detoxification utilizing plasma filtration. 1976. Ther Apher 2000; 4:15-22. [PMID: 10728497 DOI: 10.1046/j.1526-0968.2000.00233.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
43
|
Malchesky PS, Asanuma Y, Zawicki I, Blumenstein M, Calabrese L, Kyo A, Krakauer R, Nosé Y. On-line separation of macromolecules by membrane filtration with cryogelation. 1980. Ther Apher 2000; 4:34-7. [PMID: 10728501 DOI: 10.1046/j.1526-0968.2000.00238.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
44
|
Takano T, Nakata K, Yoshikawa M, Maeda T, Glueck J, Fujisawa A, Makinouchi K, Yokokawa M, Murabayashi S, Nosé Y. Development of an antithrombogenic and antitraumatic blood pump: the Gyro C1E3. ASAIO J 2000; 46:123-7. [PMID: 10667730 DOI: 10.1097/00002480-200001000-00028] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The Gyro C1E3 is a centrifugal blood pump. Its antithrombogenic and antitraumatic blood features were demonstrated by prior studies. Based upon these studies, a mass production model of the C1E3 is becoming commercially available. Therefore, this feasibility study was conducted using the mass production models of the Gyro C1E3 for long-term cardiac assist in ex vivo animal experiments. Five healthy calves were used and 15 pump heads were applied for different time periods (Group 1, 30 days; Group 2, 14 days; Group 3, 10 and 7 days; Group 4, 4 days; and Group 5, 2 days). Activated clotting time (ACT) was kept at 200-250 sec. All five calves demonstrated neither abnormal signs nor abnormal blood examination data throughout the experiment. During necropsy, no thromboembolism was found in any downstream organs. Groups 1-4 showed thrombi inside the pump heads while two pumps in Group 5 had no thrombi formations. Bearing deformation or possible wear did not increase after 2 days of pumping. The C1E3 is capable of long-term assist circulation. However, after 2 days of pumping, careful observation is necessary since thrombi may occur inside the pump when ACT is controlled under 250 sec. During the weaning stage or low flow (under 2 L/min), over 250 sec of ACT is recommended to assure the safety of the patient.
Collapse
Affiliation(s)
- T Takano
- Baylor College of Medicine, Department of Surgery, Houston TX 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Hata M, Shiono M, Orime Y, Yagi S, Yamamoto T, Okumura H, Kimura S, Sezai A, Kashiwazaki S, Choh S, Negishi N, Sezai Y, Matsui T, Suzuki M, Nakata K, Nosé Y. A clinical use of the Kyocera Gyro C1E3 centrifugal pump. Artif Organs 2000; 24:76-8. [PMID: 10677162 DOI: 10.1046/j.1525-1594.2000.06339-3.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The Kyocera Gyro C1E3 centrifugal blood pump was clinically applied for a cardiopulmonary bypass (CPB) of coronary artery bypass grafting (CABG). The patient was 72-year-old male with postinfarction unstable angina. The surgery was carried out on November 20, 1998. The air inside the pump was easily and quickly removed, and its controllability was excellent. The pump flow during operation was maintained 2.2 L/m2. Total CPB time was 173 min. Perioperative parameters of hemolysis and cytotoxicity were not remarkably changed. Macroscopically and microscopically, there were no thrombi inside the pump after usage. This is the first reported case of clinical use of the Kyocera Gyro C1E3 pump.
Collapse
Affiliation(s)
- M Hata
- Second Department of Surgery, Nihon University School of Medicine, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
In 1963, one of the abstracts we submitted for the Ninth ASAIO Congress entitled "Hemodialysis at Home: Utilizing Domestic Electric Washing Machine" by Y. Nosé and J. Mikami was rejected. At that time, leading ASAIO nephrologists, including W. J. Kolff, B. H. Scribner, and J. P. Merrill, did not favor patients dialyzing at home in spite of it being the only means of keeping renal failure patients alive. Also at that time, many patients died because of the unavailability of hemodialysis in hospitals. However, in 1965 both Dr. Scribner's group in Seattle and Dr. Merrill's group in Boston initiated a home hemodialysis program. This program was further expanded in many centers, including Dr. Kolff's at Cleveland Clinic. Later, home hemodialysis was proven a safe, effective, yet inexpensive method of treating chronic renal insufficiency patients.
Collapse
Affiliation(s)
- Y Nosé
- Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
| |
Collapse
|
47
|
Abstract
In 1993, the development began of a small axial flow blood pump, the DeBakey ventricular assist device (VAD). The material was recently converted to a titanium alloy, and a waterproof pump package was incorporated for long-term intracorporeal circulation. Thirteen intrathoracic implantations in calves were achieved. Nine animals survived the 2 week perioperative period and were supported for a range of 26-93 days. The first study had low flow due to poor anatomical fit of the straight cannula. In contrast, a curved cannula used subsequently provided a good anatomical fit with sufficient flow. Mean flow of 4.4 L/min was sustained with 9,900 rpm and required power was an average of 8.8 W. No thromboembolic evidences were observed in any case, and the plasma free hemoglobin level was maintained lower than 5 mg/dl, except in the early postoperative period. Three animals were terminated because of bleeding due to anticoagulant mismanagement. Electric interference (n = 1) and drive line breakage/fault (n = 2) were observed as device-related failures. Minor modifications were made to the drive line. In conclusion, the DeBakey VAD demonstrated adequate basic performance and biocompatibility. The highly reliable mechanical components and improved electrical parts are promising for a long-term implantable cardiac prosthesis.
Collapse
Affiliation(s)
- E Tayama
- Department of Surgery, Baylor College of Medicine, Houston, TX, USA
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Ikeda T, Nosé Y, Korata T, Numakura H, Koiwa M. The homogeneity ranges of the L12-type intermetallic compounds Ni3Ga and Ni3Ge. ACTA ACUST UNITED AC 1999. [DOI: 10.1361/105497199770340617] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
49
|
Nosé Y. Balancing (yin-yang) hypothesis for assessment of effective apheresis therapies. Ther Apher 1999; 3:280-6. [PMID: 10608718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
In the past, the therapeutic effects of apheresis were thought to be due to effective removal of pathological macromolecules and leukocytes. However, the removal of these components did not necessarily produce a lower level of these components in circulating blood. Very often a rebound phenomenon took place, particularly in leukocyte kinetics after apheresis procedures, and an increased level of circulating leukocytes was demonstrated. Thus, the assessment of the clinical effects of apheresis procedures was very difficult to discuss in terms of the removal of pathological macromolecules and/or leukocytes alone. A balancing (yin-yang) hypothesis is thus proposed to be able to understand more realistically the clinical efficacy of therapeutic apheresis.
Collapse
Affiliation(s)
- Y Nosé
- Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
| |
Collapse
|
50
|
Andrade A, Nicolosi D, Lucchi J, Biscegli J, Arruda AC, Ohashi Y, Mueller J, Tayama E, Glueck J, Nosé Y. Auxiliary total artificial heart: A compact electromechanical artificial heart working simultaneously with the natural heart. Artif Organs 1999; 23:876-80. [PMID: 10491037 DOI: 10.1046/j.1525-1594.1999.06273.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Leading international institutions are designing and developing various types of ventricular assist devices (VAD) and total artificial hearts (TAH). Some of the commercially available pulsatile VADs are not readily implantable into the thoracic cavity of smaller size patients because of size limitation. The majority of the TAH dimensions requires the removal of the patients' native heart. A miniaturized artificial heart, the auxiliary total artificial heart (ATAH), is being developed in these authors' laboratories. This device is an electromechanically driven ATAH using a brushless direct current (DC) motor fixed in a center metallic piece. This pusher plate-type ATAH control is based on Frank-Starling's law. The beating frequency is regulated through the change of the left preload, assisting the native heart in obtaining adequate blood flow. With the miniaturization of this pump, the average sized patient can have the surgical implantation procedure in the right thoracic cavity without removing the native heart. The left and right stroke volumes are 35 and 32 ml, respectively. In vitro tests were conducted, and the performance curves demonstrate that the ATAH produces 5 L/min of cardiac output at 180 bpm (10 mmHg of left inlet mean pressure and 100 mm Hg of left outlet mean pressure). Taking into account that this ATAH is working along with the native heart, this output is more than satisfactory for such a device.
Collapse
Affiliation(s)
- A Andrade
- Department of Bioengineering, Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|